Imaging study using a new tracer to find cancer
Part of Brain & nervous system, Cancer, Digestive system, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a special imaging agent, [89Zr]DFO-YS5, to see if it can help detect and map certain cancers (including malignant peripheral nerve sheath tumors, bladder cancer, and other solid tumors) during PET scans. It may help doctors see cancerous lesions more clearly.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with malignant peripheral nerve sheath tumor, bladder cancer, or another solid tumor.
- You have at least one soft tissue tumor that is 1 cm or larger on a CT, MRI, or PET scan (or a smaller bladder tumor confirmed by cystoscopy).
- You are physically able to undergo a PET-CT or PET-MRI scan.
- You are 18 years or older.
- You are generally well enough to carry out daily activities (ECOG score of 2 or less, or Karnofsky score of 50% or higher).
- Your liver and kidney function test results are within study limits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase trial tests a new imaging agent called 89Zr-DFO-starPEG that may help doctors see solid tumors more clearly on PET scans. It is a safety and imaging study, not a treatment, and may help find tumors in people with various types of cancer.
This trial tests a new imaging agent (18F-TRX) to see if it can better detect cancer spread in people with advanced solid tumors. It is designed for patients with specific cancers like high-grade brain tumors, advanced kidney cancer, or prostate cancer that has stopped responding to hormone therapy.
This study tests whether a new imaging agent, MNPR-101-DFO*-89Zr, can find solid tumors and measure their uPAR levels. It might help doctors better understand your cancer and guide future treatment decisions.
This early-stage trial tests a new radioactive tracer called [68Ga]Ga-R54 that helps doctors see certain advanced cancers (like breast, lung, colon, ovary, pancreas, or multiple myeloma) on PET scans. The tracer targets a specific protein (CXCR4) found on cancer cells, which may help doctors better detect and understand your cancer.
This trial tests a new type of PET scan that uses a special antibody to find a marker called Trop2 on many common solid tumors. It may help doctors see tumors more clearly without needing a biopsy.
This study uses a special PET scan to see if a new imaging agent can help find and monitor certain solid tumors. It is for people with colon, rectal, sarcoma, breast, lung, head and neck, esophageal, stomach, pancreas, bladder cancers, or glioblastoma who have had standard treatment before surgery.
Hear when a new Bladder Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.